Extended wait for injectable ARVs

Sharon Mathala | Monday July 14, 2025 16:53

Ookeditse was responding to a question from Member of Parliament (MP) for Nkange, Motlhaleemang Moalosi, who sought to understand the reasons behind the delay in introducing injectable ARVs, which were approved back in 2022.

The assistant minister explained that although its use was approved some time ago, the product has not been readily available on the global market, as research institutions had acquired most of the available stock, leaving very little for treatment programmes.

“However, there is a flicker of hope with injectable ARVs, as a promising new product called Lenacapavir is emerging, and the Cabotegravir combination is also being revived. That said, it is unlikely that these injectable ARVs will be available for use in Botswana before the end of 2025,” Ookeditse said.

The ministry believes that injectable ARVs offer significant benefits as a long-acting form of treatment, particularly in terms of dosing frequency, convenience, and privacy.

“Not having to take medication daily could come as a huge relief to some. And, because injectable ARVs so far have to be administered by a doctor or nurse, there is no need to store your own medication. So, no carrying it around and no risk of people finding out about your HIV status. This, therefore, reduces stigma and discrimination,” the assistant minister shared.

“With improved treatment adherence, patients are more likely to achieve viral suppression, meaning they are healthier and less likely to transmit the virus,” Ookeditse added.